Cancer Pain Management Market is Expected to Grow Significantly by 2034, Driven by Emerging Non-Opioid Analgesics and FDA Approvals | DelveInsight

DelveInsight's "Cancer Pain Market Insight, Epidemiology and Market Forecast - 2034" [https://www.delveinsight.com/report-store/cancer-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] report delivers an in-depth understanding of the cancer pain therapeutic landscape, including historical and forecasted epidemiology alongside current and emerging market trends across the 7MM (United States, EU4, United Kingdom, and Japan). The cancer pain market is expected to grow significantly with a decent CAGR through 2034. This growth is underpinned by several market drivers, including the increasing incidence of cancer, improved survival rates, and a growing emphasis on enhancing the quality of life for cancer patients. The cancer pain burden is particularly high in the United States, which accounts for the largest share of the cancer pain market among the 7MM, with nearly USD 1.7 billion in 2023.

Download the cancer pain market report to understand which factors are driving the cancer pain therapeutic market @ https://www.delveinsight.com/sample-request/cancer-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Cancer pain remains a common and challenging complication, affecting nearly 70-80% of patients with advanced cancer. According to DelveInsight's cancer pain epidemiological analysis, the total number of cancer pain cases in the 7MM is expected to continue rising. In 2023, the United States alone accounted for nearly 2.4 million cases of cancer pain, the highest among the 7MM. Among these cases, 1.5 million cases were attributed to direct tumor involvement. Additionally, Germany reported the highest chemotherapy-induced peripheral neuropathy incident cases in 2023 among the EU4 countries and the UK.

The report further divided the cancer pain epidemiological data into several categories, including the total number of cancer pain cases, cases specific to different causes (etiology), the incidence of chemotherapy-induced peripheral neuropathy, cases categorized by severity, cases based on pathophysiology, cases reflecting temporal variations, and the incidence of breakthrough cancer pain across the 7MM region.

Discover evolving trends in the cancer pain patient pool forecasts @ https://www.delveinsight.com/sample-request/cancer-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The current cancer pain treatment landscape is dominated by opioid analgesics, which remain the mainstay for moderate to severe pain management. Marketed drugs such as morphine, oxycodone, fentanyl, and hydromorphone are widely used, with extended-release formulations and transdermal patches offering improved convenience and sustained relief.

In addition to opioids, non-opioid medications play a crucial role in multimodal pain management strategies. These include nonsteroidal anti-inflammatory drugs (NSAIDs) and adjuvant therapies such as antidepressants and anticonvulsants. Among the current cancer pain therapies, adjuvant analgesics represent the largest market share, followed by strong opioids.

However, the long-term use of opioids presents significant challenges. Issues such as tolerance, dependence, and side effects associated with opioid use have prompted the search for alternative and adjunctive therapies.

Top pharmaceutical companies are actively shaping the cancer pain market, leveraging their expertise to address unmet needs. Key players such as Pfizer (NYSE: PPE), Purdue Pharma, Teva Pharmaceuticals (TLV: TEVA), Johnson & Johnson (NYSE: JNJ), and Daiichi Sankyo (TYO: 4568) have established a strong presence with their marketed opioid and non-opioid analgesics. In recent years, the competitive landscape has been further enriched by the entry of companies like WEX Pharmaceuticals, Centrexion Therapeutics, and Regeneron, which are advancing novel mechanisms of action and non-opioid alternatives in the pipeline.

Recent updates in the cancer pain market highlight the momentum in research and development. In January 2025, the FDA approved JOURNAVX (suzetrigine) by Vertex Pharmaceuticals (NASDAQ: VRTX), a first-in-class non-opioid analgesic for the treatment of adults with moderate-to-severe acute pain. JOURNAVX selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system, providing effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids.

Furthermore, in January 2025, Artelo Biosciences (NASDAQ: ARTL) announces the successful completion of the first cohort in a Phase I study of ART26.12, a compound targeting FABPs, specifically FABP5, which plays a role in pain, inflammation, and cancer treatment. The single ascending dose study intended to determine suitable doses for a subsequent multiple ascending dose study is planned for the second half of 2025.

Discover recent advancements in the cancer pain treatment landscape @ https://www.delveinsight.com/sample-request/cancer-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Looking ahead, the cancer pain market is expected to expand steadily, driven by epidemiological trends, the launch of novel therapies, and a heightened focus on patient-centric care. DelveInsight's analysis suggests that the integration of emerging drugs with established analgesics, alongside advances in diagnostics and pain assessment tools, is anticipated to enhance treatment outcomes and address longstanding challenges related to opioid use and inadequate pain control.

In summary, the cancer pain market is at a pivotal juncture, with leading pharmaceutical companies, innovative emerging drugs, and evolving treatment paradigms converging to improve the lives of cancer patients. As the epidemiological burden grows and the demand for safer, more effective pain management solutions intensifies, the market is set for sustained growth and diversification. Stakeholders across the oncology and pain management spectrum are closely monitoring developments, as the next wave of therapies promises to transform the cancer pain landscape and deliver meaningful relief to patients worldwide.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.